Uni Eropa - Kroasia - EMA (European Medicines Agency)

novartis europharm limited  - indakaterol maleat - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - onbrez breezhaler je indiciran za liječenje bronhodilatatora kod opstrukcije protoka zraka kod odraslih osoba s kroničnom opstruktivnom plućnom bolesti.

Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

medicuspharma d.o.o., rokov perivoj 6/a, zagreb - dopaminklorid - koncentrat za otopinu za infuziju - 200 mg/10 ml - urbroj: 1 ampula koncentrata za otopinu za infuziju sadrži 200 mg dopaminklorida; 1 ml koncentrata za otopinu za infuziju sadrži 20 mg dopaminklorida

Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

medicuspharma d.o.o., rokov perivoj 6/a, zagreb, hrvatska - dopaminklorid - koncentrat za otopinu za infuziju - 50 mg/5 ml - urbroj: 1 ampula koncentrata za otopinu za infuziju sadrži 50 mg dopaminklorida 1 ml koncentrata za otopinu za infuziju sadrži 10 mg dopaminklorid

Kroasia - Kroasia - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

genera d.d., kalinovica, rakov potok, hrvatska - didecildimetilamonij-klorid; izopropanol - koncentrat za pripremu radne otopine - dezinfekciji površina, predmeta i opreme u stočarskoj proizvodnji

Kroasia - Kroasia - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

zik-90 d.o.o., varaždin, hrvatska - c12-16-alkildimetil-benzilamonijev klorid, didecildimetil-benzilamonijev klorid, izopropanol i glutaraldehid - koncentrirana otopina za pripremu radne otopine s vodom - dezinfekciji radnih površina, predmeta i opreme u stočarskoj proizvodnji

Uni Eropa - Kroasia - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migrena poremećaja - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

astellas d.o.o.,ilica 1, zagreb - solifenacinsukcinat tamsulozinklorid - tableta s prilagođenim oslobađanjem - 6 mg/0,4 mg - urbroj: jedna tableta sadrži sloj sa 6 mg solifenacinsukcinata, što odgovara 4,5 mg slobodne baze solifenacina, i sloj s 0,4 mg tamsulozinklorida, što odgovara 0,37 mg slobodne baze tamsulozina

Uni Eropa - Kroasia - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatske neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.